TUCSON, Ariz.--(BUSINESS WIRE)--On May 1, the Centers for Medicare and Medicaid Services (CMS) issued its final National Coverage Decision (NCD) to reimburse the CardioWest™ temporary Total Artificial Heart (TAH-t) as part of FDA studies that meet CMS specifications.
